Jessica L. Fleming, Ph.D.
Affiliations: | 2012 | Molecular Cellular and Developmental Biology | Ohio State University, Columbus, Columbus, OH |
Area:
Cell Biology, OncologyGoogle:
"Jessica Fleming"Parents
Sign in to add mentorAmanda E. Toland | grad student | 2012 | Ohio State | |
(Utilizing Cancer Resistant and Susceptible Mice to Identify the Genetic Contributions to Cutaneous Squamous Cell Carcinoma Susceptibility.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Bell EH, Zhang P, Shaw EG, et al. (2020) Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902983 |
Bell EH, Pugh SL, Fisher BJ, et al. (2020) Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424. Journal of Clinical Oncology. 38: 2518-2518 |
Moran NE, Thomas-Ahner JM, Fleming JL, et al. (2019) Single Nucleotide Polymorphisms in β-Carotene Oxygenase 1 are Associated with Plasma Lycopene Responses to a Tomato-Soy Juice Intervention in Men with Prostate Cancer. The Journal of Nutrition |
Fabian D, Bell EH, McElroy JP, et al. (2019) A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed glioblastoma utilizing global microRNA expression data. Journal of Clinical Oncology. 37: 2044-2044 |
Bell EH, Won M, Fleming JL, et al. (2019) Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. Journal of Clinical Oncology. 37: 2002-2002 |
Sebastian E, Cui T, Bell EH, et al. (2019) RDNA-14. RADIATION-INDUCED miR-4516 CONTRIBUTES TO RADIO-RESISTANCE AND PROMOTES AGGRESSIVE PHENOTYPE IN GLIOBLASTOMA Neuro-Oncology. 21 |
Beyer SJ, Bell EH, McElroy JP, et al. (2018) Oncogenic is differentially regulated in wild-type vs. mutant gliomas. Oncotarget. 9: 37097-37111 |
Cui T, Bell EH, McElroy J, et al. (2018) miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene |
Bell EH, Zhang P, Fisher BJ, et al. (2018) Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Jama Oncology |
Meng W, Bell EH, Singh R, et al. (2018) Gene-27. Genome-Wide Dna Methylation Profiling In Grade Ii And Iii Gliomas Reveals A Subset Of Genes With Prognostic Significance Controlled By Promoter Methylation Neuro-Oncology. 20 |